| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Clindamycin palmitate HCl (EC 244-398-6; U-21251; U21251; Cleocin; Clinsol; EC2443986; Clinacin, Dalacin),
the Palmitate ester form and hydrochloride salt of Clindamycin which is a semisynthetic lincomycin analog, is a potent
antibiotic acting as
a protein synthesis inhibitor. It can be used for treatment of many bacterial
infections such as bone or joint infections, middle ear
infections, strep throat, pneumonia, pelvic inflammatory disease, and
endocarditis. It can also be used for treatment of acne, and some cases
of methicillin-resistant Staphylococcus
aureus
| Targets |
Bacterial protein synthesis
|
|---|---|
| ln Vitro |
Clindamycin palmitate hydrochloride is a water-soluble hydrochloride salt formed by esterification of clindamycin with palmitic acid. This compound is inactive in vitro but undergoes rapid in vivo hydrolysis to release clindamycin, the antibacterially active moiety. A total of 12 impurities were detected using isocratic reverse-phase high-performance liquid chromatography with refractive index detection, ranging from 0.05% to 0.5% of the sample. The molecular weights of these impurities were determined by liquid chromatography-mass spectrometry analysis. Two impurities were identified as residual starting materials, while the remaining impurities were isolated from crude samples or enriched mother liquors using reverse-phase preparative HPLC. Based on comprehensive spectral data—including proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance, mass spectrometry, and infrared spectroscopy—the structures of these impurities were characterized as follows: clindamycin palmitate sulfoxides (alpha and beta isomers) (Impurity I), clindamycin laurate (Impurity II), lincomycin palmitate (Impurity III), clindamycin myristate (Impurity IV), epiclindamycin palmitate (Impurity V), clindamycin palmitate 3-isomer (Impurity VI), clindamycin pentadecanoate (Impurity VII), clindamycin B-palmitate (Impurity VIII), clindamycin heptadecanoate (Impurity IX), and clindamycin stearate (Impurity X). The structural elucidation of all impurities and the mechanisms underlying their formation are discussed in detail. [1]
|
| References | |
| Additional Infomation |
Clindamycin palmitate is an S-glycoside compound. Clindamycin palmitate is the palmitate hydrochloride form of clindamycin, a semi-synthetic chlorinated broad-spectrum antibiotic derived from lincomycin through chemical modification. Clindamycin palmitate is used in oral suspensions. See also: Clindamycin (containing the active ingredient).
|
| Molecular Formula |
C34H64CL2N2O6S
|
|---|---|
| Molecular Weight |
699.854
|
| Exact Mass |
698.386
|
| Elemental Analysis |
C, 58.35; H, 9.22; Cl, 10.13; N, 4.00; O, 13.72; S, 4.58
|
| CAS # |
25507-04-4
|
| Related CAS # |
Clindamycin hydrochloride;21462-39-5;Clindamycin phosphate;24729-96-2; 25507-04-4 (palmitate HCl); 21462-39-5 (HCl); 18323-44-9 (free); 58207-19-5 (HCl monohydrate)
|
| PubChem CID |
16052038
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
767.4ºC at 760 mmHg
|
| Melting Point |
141-143ºC
|
| Flash Point |
417.9ºC
|
| Vapour Pressure |
3.44E-27mmHg at 25°C
|
| LogP |
7.552
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
45
|
| Complexity |
810
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CCCCCCCCCCCCCCCC(O[C@H]1[C@@H](SC)O[C@H]([C@H](NC([C@H]2N(C)C[C@H](CCC)C2)=O)[C@@H](Cl)C)[C@H](O)[C@@H]1O)=O.Cl
|
| InChi Key |
GTNDZRUWKHDICY-DJHAJVGHSA-N
|
| InChi Code |
InChI=1S/C34H63ClN2O6S.ClH/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-21-27(38)42-32-30(40)29(39)31(43-34(32)44-5)28(24(3)35)36-33(41)26-22-25(20-7-2)23-37(26)4/h24-26,28-32,34,39-40H,6-23H2,1-5H3,(H,36,41)1H/t24-,25+,26-,28+,29+,30-,31+,32+,34+/m0./s1
|
| Chemical Name |
(2R,3R,4S,5R,6R)-6-((1S,2S)-2-chloro-1-((2S,4R)-1-methyl-4-propylpyrrolidine-2-carboxamido)propyl)-4,5-dihydroxy-2-(methylthio)tetrahydro-2H-pyran-3-yl
palmitate hydrochloride
|
| Synonyms |
U 25179E; U-25179-E U25179E; U21251F; U-21251-F; Clinsol EC; 244-398-6; EC2443986; U 21251 F;
Clindamycin palmitate HCl; CLINDAMYCIN PALMITATE HYDROCHLORIDE; 25507-04-4; Cleocin Pediatric; Clindamycin 2-palmitate hydrochloride;
U-21251; EC-244-398-6; U 21251; Clindamycin; Cleocin, Clinacin, Dalacin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~178.61 mM)
H2O : ~50 mg/mL (~71.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4289 mL | 7.1444 mL | 14.2888 mL | |
| 5 mM | 0.2858 mL | 1.4289 mL | 2.8578 mL | |
| 10 mM | 0.1429 mL | 0.7144 mL | 1.4289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
